SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

Pantoprazole-d_6

Item No. 28483

CAS Registry No.: 922727-65-9
Formal Name: 6-(difluoromethoxy)-2-[[[3,4-di(methoxy-d_3)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole
MF: $C_{16}H_9D_6F_2N_3O_4S$
FW: 389.4
Chemical Purity: ≥98% (Pantoprazole)
Deuterium Incorporation: ≥99% deuterated forms (d_1-d_6); ≤1% d_0
Supplied as: A solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Pantoprazole-d_6 is intended for use as an internal standard for the quantification of pantoprazole (Item No. 21345) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated *versus* unlabeled).

Pantoprazole-d_6 is supplied as a solid. A stock solution may be made by dissolving the pantoprazole-d_6 in the solvent of choice. Pantoprazole-d_6 is soluble in the organic solvent DMSO, which should be purged with an inert gas.

Description

Pantoprazole is a proton pump inhibitor that inhibits H^+/K^+-ATPase activity in porcine gastric membrane vesicles with an IC_{50} value of 6.8 µM.[1] It reduces basal gastric acid secretion in pylorus-ligated rats (ED_{50} = 1.3 mg/kg) and inhibits mepirizole-induced increases in gastric acid secretion in an anesthetized rat model of gastric fistula (ED_{50} = 0.8 mg/kg).[2] Pantoprazole inhibits formation of mepirizole-induced duodenal lesions in rats (ED_{50} = 0.5 mg/kg). Formulations containing pantoprazole have been used in the treatment of gastroesophageal reflux disease (GERD) and hypersecretory conditions, including Zollinger-Ellison Syndrome.

References

1. Beil, W., Staar, U., and Sewing, K.F. Pantoprazole: A novel H^+/K^+-ATPase inhibitor with an improved pH stability. *Eur. J. Pharmacol.* **218(2-3)**, 265-271 (1992).
2. Takeuchi, K., Konaka, A., Nishijima, M., *et al.* Effects of pantoprazole, a novel H^+/K^+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: A comparative study with omeprazole and lansoprazole. *J. Gastroenterol. Hepatol.* **14(3)**, 251-257 (1999).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM